Related Experiment Video
Updated: Jun 26, 2026

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
Expert judgments of pandemic influenza risks
W Bruine De Bruin1, B Fischhoff, L Brilliant
1Department of Social and Decision Sciences, Carnegie Mellon University, Pittsburgh, PA 15213, USA. wandi@cmu.edu
Abstract:
Structured surveys were conducted with 19 medical experts, and 17 non-medical experts in related fields, attending a meeting about pandemic influenza. Respondents gave quantitative judgments for key variables potentially affecting the extent of a possible H5N1 pandemic. The medical experts saw about a 15% (median) chance of efficient human-to-human transmission, in the next 3 years. Should it occur, they saw almost no chance of there being adequate vaccines or antiviral responses. They saw varying chances of six other mitigation strategies reducing the threat, expressing the greatest faith in improved surveillance. Compared to the medical experts, the non-medical experts saw much higher chances of both human-to-human transmission and of effective vaccine and antiviral responses being available. The medical experts and the non-medical experts had similar, dire predictions for the extent of casualties, should transmission occur in the next 3 years. Their responses to open-ended questions revealed some of the theories underlying these beliefs.
Related Concept Videos
Influenza
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Relative Risk
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Infectious Diseases and Their Occurrence
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

